US firm sets â¹5.4 crore price for blindness-treating therapy
US-based pharmaceutical startup Spark Therapeutics has announced the cost of its gene therapy that injects a virus into the patients' eyes at $425,000 per eye, or $850,000 (nearly â¹5.4 crore) for most patients. Spark's drug, Luxturna, treats a rare form of blindness called retinal dystrophy that occurs when patients inherit a non-working mutated gene from each parent.